Leading CDMO adopts Veeva Vault QMS, Vault QualityDocs, and Vault Training to standardize quality processes and manage GxP content across its organization
BARCELONA, Spain, Dec. 19, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Recipharm, a global contract development and manufacturing organization (CDMO), will use Veeva Vault QMS, Veeva Vault QualityDocs, and Veeva Vault Training to streamline its quality operations. Veeva quality applications will help Recipharm achieve greater quality oversight, use resources more effectively, accelerate validation, and maintain inspection readiness.
"Harmonizing quality processes and GxP documentation across Recipharm sites will make our quality operations more efficient and scalable," said Vanessa Nardolillo, head of quality management and regulatory affairs at Recipharm. "With Veeva Vault Quality, Recipharm is setting a new global standard for quality management, site collaboration, and compliance. The system will enable us to provide our customers with a standard approach to quality. It forms a key part of our focus on continuous improvement, to unleash excellence in quality across our services."
Recipharm offers manufacturing services to pharmaceutical and medical device companies. Vault QMS will help Recipharm gain greater control and visibility into quality processes, with Vault QualityDocs, driving efficient GxP content management and information sharing among sites. With Vault Training, Recipharm can deploy learning content and curricula to help ensure its GxP effectiveness and compliance.
"Unifying quality processes, content, and training on Veeva Vault Quality will help Recipharm keep contract development and manufacturing on track as it continues to scale," said Rob Gaertner, vice president of quality strategy for Europe at Veeva. "We're excited to partner with Recipharm in evolving its quality operations."
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy WhittakerVeeva Systems+49-695-095-5486jeremy.whittaker@veeva.com
Logo - https://mma.prnewswire.com/media/1488285/4462725/Veeva_Systems_Logo.jpg
.jpg)
